Matthew Meriggioli to Myasthenia Gravis
This is a "connection" page, showing publications Matthew Meriggioli has written about Myasthenia Gravis.
Connection Strength
5.402
-
Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis. Neurotherapeutics. 2016 Jan; 13(1):118-31.
Score: 0.497
-
Functional defect in regulatory T cells in myasthenia gravis. Ann N Y Acad Sci. 2012 Dec; 1274:68-76.
Score: 0.401
-
Impaired regulatory function in circulating CD4(+)CD25(high)CD127(low/-) T cells in patients with myasthenia gravis. Clin Immunol. 2012 Dec; 145(3):209-23.
Score: 0.397
-
Granulocyte macrophage colony-stimulating factor treatment of a patient in myasthenic crisis: effects on regulatory T cells. Muscle Nerve. 2012 Sep; 46(3):449-53.
Score: 0.395
-
Muscle autoantibodies in myasthenia gravis: beyond diagnosis? Expert Rev Clin Immunol. 2012 Jul; 8(5):427-38.
Score: 0.390
-
In vivo adsorption of autoantibodies in myasthenia gravis using Nanodisc-incorporated acetylcholine receptor. Exp Neurol. 2010 Oct; 225(2):320-7.
Score: 0.340
-
Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009 May; 8(5):475-90.
Score: 0.313
-
Myasthenia gravis with anti-acetylcholine receptor antibodies. Front Neurol Neurosci. 2009; 26:94-108.
Score: 0.312
-
IVIG in myasthenia gravis: getting enough "bang for the buck". Neurology. 2007 Mar 13; 68(11):803-4.
Score: 0.270
-
Myasthenia gravis: diagnosis. Semin Neurol. 2004 Mar; 24(1):31-9.
Score: 0.219
-
Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology. 2003 Nov 25; 61(10):1438-40.
Score: 0.215
-
Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized study. J Clin Neurosci. 2024 Jan; 119:76-84.
Score: 0.215
-
Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study. Ann N Y Acad Sci. 2003 Sep; 998:494-9.
Score: 0.211
-
Single fiber EMG as an outcome measure in myasthenia gravis: results from a double-blind, placebo-controlled trial. J Clin Neurophysiol. 2003 Sep-Oct; 20(5):382-5.
Score: 0.211
-
Myasthenia gravis. Clin Neuropharmacol. 2000 Nov-Dec; 23(6):291-5.
Score: 0.174
-
Treatment of myasthenia gravis with mycophenolate mofetil: a case report. Muscle Nerve. 2000 Aug; 23(8):1287-9.
Score: 0.171
-
Severe Exacerbation of Myasthenia Gravis Associated with Checkpoint Inhibitor Immunotherapy. J Neuromuscul Dis. 2017; 4(2):169-173.
Score: 0.133
-
Introduction for myasthenia gravis and related disorders. Ann N Y Acad Sci. 2012 Dec; 1274:vii-viii.
Score: 0.100
-
Introduction for Myasthenia Gravis and Related Disorders. Ann N Y Acad Sci. 2012 Dec; 1275:vii-viii.
Score: 0.100
-
Recommendations for myasthenia gravis clinical trials. Muscle Nerve. 2012 Jun; 45(6):909-17.
Score: 0.097
-
Predictive value of serum anti-C1q antibody levels in experimental autoimmune myasthenia gravis. Neuromuscul Disord. 2006 Feb; 16(2):137-43.
Score: 0.062
-
Advances in the diagnosis of neuromuscular junction disorders. Am J Phys Med Rehabil. 2005 Aug; 84(8):627-38.
Score: 0.060
-
Myasthenia gravis patients with low plasma IL-6 and IFN-gamma benefit from etanercept treatment. J Autoimmun. 2005 May; 24(3):261-8.
Score: 0.059
-
Etanercept treatment in corticosteroid-dependent myasthenia gravis. Neurology. 2004 Dec 28; 63(12):2390-2.
Score: 0.058